Literature DB >> 23702647

Analysis of CD8+ and CD4+ cells in oral squamous cell carcinoma and their association with lymph node metastasis and histologic grade of malignancy.

Joabe dos antos Pereira1, Márcia Cristina da Costa Miguel, Lélia Maria Guedes Queiroz, Éricka Janine Dantas da Silveira.   

Abstract

This study aimed to analyze CD8 and CD4 cells in oral squamous cell carcinoma and to correlate it with prognostic indicators. The sample was composed of 50 cases. Clinical data and histologic grade of malignancy were obtained. Specimens were submitted to immunohistochemistry. Cells were counted in 10 fields at the tumor invasion front and expressed as median. CD8 cells were more frequent in nonmetastatic lesions (18.5) and in low-grade specimens (18.2) (P<0.05). CD4 cells were equally distributed in nonmetastatic and metastatic lesions (4.5). In addition, they were slightly more frequent in low-grade lesions (4.7). None of these correlations were significant (P>0.05). CD8/CD4 ratio was higher in cases without metastasis (3.57) and in low-grade lesions (3.62) (P>0.05). Probably, CD8 cells are the most effective and important cells in the host immune responses against oral squamous cell carcinoma. In addition, CD4 cells could indirectly influence the host protection through regulation of CD8 recruitment and activation.

Entities:  

Mesh:

Year:  2014        PMID: 23702647     DOI: 10.1097/PAI.0b013e31828df3c9

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

Review 1.  Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges.

Authors:  Tuba M Ansary; M D Razib Hossain; Mayumi Komine; Mamitaro Ohtsuki
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

2.  The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.

Authors:  Jie Wang; Shu Tian; Ji Sun; Jiahao Zhang; Lan Lin; Chunyan Hu
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.